Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Souvenaid

Picture from the DPharm conference alongside text and branding

DPHARM2023 – Five key themes impacting clinical trials today

Throughout three fascinating days of conference, some key themes emerged that are impacting study teams and the effectiveness of their clinical trials on a daily basis.

Cuttsy + Cuttsy

- PMLiVE

Survey reveals ongoing chemotherapy shortages in US cancer centres

Carboplatin shortages increased by 2% since the first NCCN survey in June 2023

EU flag

New EU study highlights psychological challenges of living with skin diseases

Almost half of European adults declared at least one dermatological disease

- PMLiVE

Differences in immune responses could optimise future COVID-19 vaccines

Vulnerability to different mutations was linked to previous infections and vaccination

- PMLiVE

Flexible working: a fad or the future?

As the Flexible Working Bill gets written into UK law, we took a look at what this means for businesses of all sizes and specialities.

Cuttsy + Cuttsy

Icons of hand holding brain and lightbulb lighting up with brain inside

Looking for a job head first

During Health Information Week, we reflected on mental health and wellbeing within the workplace. Cuttsy+Cuttsy’s mental health first aider and HR Manager, Kate McCabe, shared some thoughts on what mental...

Cuttsy + Cuttsy

- PMLiVE

If we don’t heal the healers, who will heal us?

By Claire Knapp

- PMLiVE

PM Society Awards 2024 open for entries

Twist Health will be the headline sponsor of the awards for the second year running

- PMLiVE

Solving your biggest patient recruitment and retention challenges

Clinical trial patient recruitment and retention remains one of the key challenges to successfully bringing a new therapeutic to market. An estimated 85% of clinical trials face delays due to...

- PMLiVE

Bristol Myers Squibb to acquire Mirati Therapeutics for up to $5.8bn

The transaction would mark a significant boost to the US drugmaker’s oncology portfolio

- PMLiVE

AstraZeneca’s Forxiga shows promise in paediatric type 2 diabetes trial

The prevalence of type 2 diabetes in children and adolescents is increasing globally

- PMLiVE

Merck shares positive results for Keytruda in phase 3 bladder cancer study

Over 82,000 people in the US will be be diagnosed with bladder cancer in 2023

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links